Achieve Higher AAV Productivity With The Next-Generation Transfection Reagent TransIT®-AAViator

The demand for gene therapy is rapidly increasing, requiring efficient and cost-effective manufacturing of recombinant AAV therapeutics. Legacy processes often struggled to produce sufficient doses for even a single patient, highlighting the need for improved manufacturing methods. Mirus Bio's TransIT^®-AAViator is a next-generation transfection reagent designed to address these challenges.  

This innovative transfection system features an optimized lipid and polymer formulation that requires less plasmid DNA and transfection reagent, leading to improved AAV productivity and a streamlined workflow. When used in conjunction with ReviT AAV Enhancer, TransIT-AAViator significantly increases AAV titers and the percentage of full AAV capsids across various serotypes. This results in a robust and scalable system that can yield multi-fold improvements in titer and percent full AAV capsids, ultimately leading to a substantial reduction in the cost per dose.  

Download the poster to learn more about the TransIT-AAViator Transfection System and its benefits for AAV manufacturing.